Sumitomo Mitsui Trust Holdings Inc. Sells 141,629 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Sumitomo Mitsui Trust Holdings Inc. reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 4.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,257,689 shares of the company’s stock after selling 141,629 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned 3.38% of Intellia Therapeutics worth $72,907,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of NTLA. Blue Trust Inc. boosted its position in shares of Intellia Therapeutics by 1,664.3% in the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after acquiring an additional 1,398 shares during the period. Signaturefd LLC raised its holdings in Intellia Therapeutics by 89.3% in the 4th quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock valued at $49,000 after acquiring an additional 751 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Intellia Therapeutics by 1,322.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock worth $59,000 after acquiring an additional 2,459 shares during the period. Daiwa Securities Group Inc. increased its position in shares of Intellia Therapeutics by 35.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock valued at $93,000 after purchasing an additional 793 shares during the period. Finally, Spire Wealth Management increased its position in shares of Intellia Therapeutics by 3,789.0% during the fourth quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock valued at $119,000 after purchasing an additional 3,789 shares during the period. Institutional investors own 88.77% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on NTLA shares. Canaccord Genuity Group restated a “buy” rating and issued a $73.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, June 27th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. Finally, JPMorgan Chase & Co. decreased their price target on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $61.58.

Intellia Therapeutics Stock Down 1.0 %

NASDAQ:NTLA traded down $0.24 during mid-day trading on Friday, reaching $22.63. 1,057,720 shares of the company were exchanged, compared to its average volume of 1,550,436. The stock has a market cap of $2.18 billion, a PE ratio of -4.22 and a beta of 1.81. Intellia Therapeutics, Inc. has a 12 month low of $19.37 and a 12 month high of $39.01. The company has a fifty day moving average of $24.17 and a 200 day moving average of $25.17.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $19.68 million. During the same period in the prior year, the company posted ($1.40) earnings per share. Intellia Therapeutics’s quarterly revenue was down 48.5% compared to the same quarter last year. On average, equities research analysts anticipate that Intellia Therapeutics, Inc. will post -4.98 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.